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Salmonella choleraesuis is one of the least commonly reported nontyphoidal salmonellae in the United States, accounting for only
0.08% and ranking lower than 20th place among all human source salmonellosis reported to the CDC in 2009. In the state of
Connecticut, only 12 cases have been reported since 1998 and our case is the only case since 2008. We report a case of invasive
Salmonellosis caused by Salmonella choleraesuis in a patient on an antitumor necrosis factor-𝛼 agent (adalimumab) who recently
returned from a trip to the Dominican Republic.
1. The Patient
A 52-year-old white male with a history of Crohn’s disease,
nonalcoholic steatohepatitis, and liver cirrhosis, living in
Hartford, CT, USA, presented in April 2011 with a four-day
history of fever, chills, and severe headache all of which began
approximately one week after his return from the Dominican
Republic where he had travelled for a 10-day vacation with a
group of family and friends. He had no abdominal pain or
diarrhea but had some nausea and vomiting. He stayed at a
“5-star resort” from where he obtained all his food. He drank
only bottled water although he used ice which he obtained
locally. He did not receive any vaccinations or prophylaxis
prior to his travel. He had been on adalimumab (humira),
40mg injections weekly, and 6-mercaptopurine, 75mg by
mouth daily for the past 2 years for crohn’s disease diagnosed
more than 20 years ago.
Physical examination was remarkable for a maximum
temperature of 103.8. He had a normal abdominal exam-
ination. Pertinent laboratory findings include a WBC
of 3,500/𝜇L and two sets of blood cultures that grew
Salmonella choleraesuis which was susceptible to ceftriax-
one and ciprofloxacin with a ciprofloxacin MIC reported
as <0.2 𝜇g/mL. However nalidixic acid sensitivity was not
reported. Stool culture had no growth. He had a normal CSF
examination and a negative HIV ELISA.
The patient was initially treated with intravenous ceftri-
axone with good clinical response, defervescing within 36
hours with no growth from blood cultures obtained two
days after antibiotics were instituted. Since the organism was
also susceptible to ciprofloxacin, the patient was discharged
home on a two-week course of oral ciprofloxacin. However he
returned to the hospital a month later with similar symptoms
as well as recurrent bacteremia with the same organism.
This time nalidixic acid sensitivity was reported as resistant
so ciprofloxacin was not recommended for therapy. Further
workup to evaluate for involvement of extra intestinal sites
including a transesophageal echocardiogram and CAT scan
of the chest and abdomenwith IV contrastwas unremarkable.
His adalimumab was temporarily discontinued and he was
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Figure 1: Laboratory-confirmed Salmonella isolates from human
sources reported to CDC by serotype and year, 1999–2009; com-
paring the number of S. choleraesuis isolates to the most frequently
reported serotypes.
discharged home on a one-month course of intravenous
ceftriaxone and has done well without any recurrence after
six months of follow up.
2. Literature Review and Discussion
Salmonella choleraesuis is a serotype of Salmonella enter-
ica sub specie enterica. S. choleraesuis human infection is
extremely rare in the United States. From the CDC public
health laboratory information system (PHLIS) 2009 data, it
accounted for only 0.08%, ranking lower than 20th place
among all human salmonellosis isolates in the United States
[1] (see Figure 1). Connecticut has only reported 12 cases since
1998 and our case is the only case since 2008 according to the
Connecticut department of public health.
S. choleraesuis primarily causes enterocolitis and sep-
ticemia in pigs and is only very rarely isolated from other
reservoirs; hence, most human infection is acquired from
pigs [2, 3]. Studies have shown that human isolates of
this organism are genetically and epidemiologically closely
related to the isolates obtained from infected swine [2, 4].
The organism is shed by carrier and infected animals which
can result in continued environmental contamination and
reinfection of new animals by horizontal transmission [2, 3].
Studies citing US data from the beginning of the last decade
report that S. choleraesuis was responsible for more than 90%
of salmonellosis in swine [2, 3]. However, more recent CDC
data from the 2009 annual Salmonella summary revealed that
it caused only 2.4% of clinical porcine salmonellosis with
S. typhimurium var. 5- being the highest reported at 26.6%
[1].
Most case reviews on this organism are from Taiwan
where it ranked as the second commonest Salmonella causing
human disease for most of the 1990s with prevalence as high
as 8% [2]. This trend continued until it began to decline
in 2004 and thereafter, with a prevalence of 4.3% in 2004
and 0.84% in 2007 [5]. The decline has been attributed to
the institution of strict antibiotic regulation in live stock by
the Taiwan department of Agriculture in 2002 as well as
the introduction of vaccination of pigs in 2004 with the live
attenuated S. choleraesuis vaccine, suisaloral (Impfstoff-werk
Dessau-Tornau GmbH, Germany) [4].
These reviews have shown that S. choleraesuis has a
higher predilection than other Salmonella serotypes to
cause primary bacteremia and focal invasive disease includ-
ing endovascular infection especially in immunosuppressed
patients with little or no intestinal manifestations as well as
a tendency for recurrent infection [2, 6]. There has been no
recent review of S. choleraesuis infection in the United States
since the series published by Allison et al. from the Medical
college of Virginia in 1969 which reviewed 19 cases diagnosed
over 13 years where all the cases had bacteremia and all had
negative stool cultures [6].
This case report describes the somewhat unusual clinical
presentation of Salmonella choleraesuis when compared to
other nontyphoidal salmonellosis. Whereas most other non-
typhoidal salmonellae cause self-limited gastroenteritis with
only 5% of patients developing bacteremia, S. choleraesuis
causes primary bacteremia in up to 70% of patients and
focal invasive, extra intestinal disease in 25–50% of patients
with a paucity of gastrointestinal symptoms especially in
the immunosuppressed, older patient [7, 8]. Multiple case
reviews have shown that immunosuppression is the most
significant risk factor for invasive salmonellosis due to this
organism [7, 8]. There is an increasing report of invasive
salmonellosis cases among patients on anti-TNF-𝛼 agents
[9, 10]. Other risk factors include age above 50, liver cirrhosis,
inflammatory bowel disease, systemic lupus erythematosus,
and diabetes mellitus. Mycotic aneurysms, osteomyelitis,
and pleuropulmonary infections are the commonest focal
infections reported [6–8].
Recurrence after appropriate and adequate antimicro-
bial treatment is a feared clinical scenario in patients with
S. choleraesuis infection [7] (see Table 1). Some of the risk
factors associated with recurrence include preexisting tissue
damage such as atherosclerotic plaques and diseased bones or
joints. Timely surgical intervention in addition to antibiotics
may prevent recurrence in patients with mycotic aneurysms
and osteomyelitis [7].
In the United States, severe Salmonella infections includ-
ing typhoid fever are treated with fluoroquinolones such as
ciprofloxacin and third-generation cephalosporins such as
ceftriaxone [1]. Resistance to nalidixic acid, an elementary
quinolone, in enterobacteriaceae correlates with decreased
susceptibility to ciprofloxacin (MIC ≥ 0.12𝜇g/mL) and pos-
sible fluoroquinolone treatment failure. The resistance of
nontyphi salmonellae to nalidixic acid and ceftriaxone in
the US averages about 2% and 2.8%, respectively, whereas
resistance to ciprofloxacin remains rare. On the contrary,
S. typhi resistance to nalidixic acid in the US is remarkably
higher at 69.1% [1]. There is no data on S. choleraesuis
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Table 1: Summary of clinical features of patients with recurrent S. choleraesuis infections. [7] Copyright © 2006 Cambridge University Press.
Reprinted with the permission of Cambridge University Press.
Patient
number Age/sex
Underlying medical
condition Initial diagnosis
Disease recurrence (source
of positive culture)
Interval between first
presentation and
second presentation
1 26/M
Bilateral femoral head
avascular necrosis s/p
total hip replacement
Osteomyelitis Osteomyelitis (drainwound) 4 months
2 69/M Diabetes mellitus,hepatocellular CA
Primary S. choleraesuis
bacteremia
Mycotic aneurysm (blood,
tissue) 3 years
3 71/M
Hypertension, bladder
transitional cell CA, ESRD
undergoing hemodialysis
Mycotic aneurysm Mycotic aneurysm (blood) 2 months
4 50/M
Hypertension, aortic
regurgitation s/p
mechanical valve
Mycotic aneurysm Mycotic aneurysm (blood) 6 months
5 48/F Nil Osteomyelitis Osteomyelitis, enterocolitis(blood, stool) 5 months
6 65/M
Hepatitis B virus
infection-related liver
cirrhosis
Primary S. choleraesuis
bacteremia
Spontaneous bacteria
peritonitis (blood, ascites) 6 months
resistance to these antibiotics in the US probably because of
the rarity of its occurrence here.
In Taiwan however, where S. choleraesuis is amajor public
health problem, studies have shown a rapidly increasing
resistance to ciprofloxacin approaching 100% [4, 11]. A
prospective, laboratory-based surveillance study of fluoro-
quinolone resistance in S. choleraesuis isolated from humans
in four major teaching hospitals across Taiwan revealed an
overall significant increase in resistance to ciprofloxacin from
32.3% in 2000 to 56.5% in 2001, 61.8% in 2002, and 71.8%
in 2003 [11]. A case series of 47 patients with S. choler-
aesuis infection from a large university hospital in Taiwan
revealed 100% resistance to Nalidixic acid, 55% resistance to
ciprofloxacin,<5% resistance to ceftriaxone, but no resistance
to cefepime, aztreonam, and the carbapenems [8]. This high
rate of resistance to the quinolones is attributed in part
to the use of quinolones in swine feed in Taiwan. These
data therefore imply that extended spectrum cephalosporins
remain the most reliable option for treating S. choleraesuis
infection in these locations but this may not apply to the
USA where ciprofloxacin resistance in nontyphi salmonellae
remains rare [1].
Our patient may have acquired his infection from the
DominicanRepublic but the literature has not shown an asso-
ciation of this infection with this location besides one case
report of a 70-year-oldmale who presented with endocarditis
caused by S. choleraesuis after returning from the Dominican
Republic [12]. In fact, there is no data on the occurrence of
S. choleraesuis in pigs or humans in the Dominican Republic.
Our patient did not report any ingestion of Pork or contact
with swine during his travel.The ice he used during his travel
may have been contaminated andmayhave been the source of
his infection. Unfortunately, data on the travel history of the
cases reported in Connecticut and other states of the United
States are not available so it is unclear if these infections were
acquired locally or abroad.
The index patient had multiple immunosuppressing con-
ditions besides being on a biologic agent that increased his
risk for invasive disease. He may likely have benefited from
a pretravel evaluation for necessary vaccinations prior to his
travel including the Salmonella typhi vaccine which he is also
at a higher risk of developing invasive disease from given his
immune status.
Nalidixic acid susceptibility testing was not done during
the patient’s initial presentation, the result of which may
have precluded the use of ciprofloxacin in the first place.
However it is not clear if the recurrence of his infection was
a result of treatment failure due to a reduced susceptibility to
ciprofloxacin or if it was a question of his immune status or
if it was a case requiring a longer duration of treatment than
the two weeks he initially received.
The 2011 CLSI guidelines did recommend nalidixic acid
susceptibility testing as a form of screening in order to
detect reduced susceptibility to ciprofloxacin in extraintesti-
nal Salmonella species that are reported as susceptible to
ciprofloxacin [13]. The problem however is that resistance
to nalidixic acid does not always infer clinical failure with
ciprofloxacin and nalidixic acid may not identify all the
mechanisms of fluoroquinolone resistance [13, 14]. Hence
in the 2012 CLSI guidelines, the need for nalidixic acid
susceptibility testing was eliminated entirely by lowering
the ciprofloxacin breakpoint (<0.06𝜇g/mL) for S. typhi and
extraintestinal Salmonella infections [13, 15].
It is possible that our patient may have benefited from a
longer duration of antibiotic treatment than the two weeks
he received during his initial presentation given his mul-
tiple immunosuppressing conditions. The important thing
to remember however is that recurrent infection with this
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organism has not been associated with inadequate or inap-
propriate antibiotic therapy although it remains to be deter-
mined what length of antibiotic therapy is deemed adequate.
Based on the data presented in this report, it appears prudent
that a third or higher generation cephalosporin should be
used to treat S. choleraesuis infection until the susceptibility
of the organism to ciprofloxacin is determined if the use of
the latter is being considered.
3. Conclusion
S. enterica serotype choleraesuis human infection is rare in
the United States. It causes invasive disease especially in
elderly, immunosuppressed patients, may not manifest with
gastroenteritis, and has a high tendency for recurrence.There
is still a lot that remains to be learned about the epidemiology,
treatment, and prevention of recurrence of this infection
especially in the United States and a travel history may be
helpful to determine the source of infection. There is a need
to address the travel requirements and evaluation of patients
on anti-TNF-𝛼 and other biologic agents travelling to disease
endemic locations.
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